Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics
Authors:
- 27 February 2021
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (7) , 2742-2750.e1
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute (R21 HL140287)
- Mayo Clinic (R21 HL140287)
- National Institutes of Health (R21 HL140287)
This publication has 27 references indexed in Scilit:
- Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma controlRespiratory Medicine, 2014
- Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysisJournal of Allergy and Clinical Immunology, 2014
- Loss of asthma control after cessation of omalizumab treatment: real life dataAdvances in Dermatology and Allergology, 2014
- Trends in cost and outcomes among adult and pediatric patients with asthma: 2000–2009Annals of Allergy, Asthma & Immunology, 2013
- After 6 years with Xolair; a 3‐year withdrawal follow‐upAllergy, 2009
- Incremental Direct Expenditure of Treating Asthma in the United StatesJournal of Asthma, 2009
- CD‐sens and clinical changes during withdrawal of Xolair after 6 years of treatmentAllergy, 2007
- External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?Thorax, 2007
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987